Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rodrigo Lago

Cardiovascular Disease Apopka, FL Medical Doctor

NPI 1821269697 CMS profile 37834

2100 Ocoee Apopka Rd Ste 120, Apopka, FL 32703

Open in the dashboard

General payments

$26,985

80 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$49,699 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Rodrigo Lago of Apopka, FL is reported in the CMS Open Payments database as having received $26,985 across 80 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $49,699 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $410 8
2024 General $1,868 27
2023 General $5,566 14
2022 General $7,230 12
2021 General $187 1
2020 General $5,663 8
2019 General $6,061 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodrigo Lago
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Rodrigo Lago were reported at $410. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Rodrigo Lago Cardiovascular Disease median Middle half National median
2019 $6,061 $450 $127–$1,392 $163
2020 $5,663 $242 $77–$751 $114
2021 $187 $335 $101–$1,037 $132
2022 $7,230 $395 $121–$1,211 $149
2023 $5,566 $443 $136–$1,283 $160
2024 $1,868 $450 $136–$1,323 $164
2025 $410 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $18,468 24 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $4,753 2 payments
  3. Abbott Laboratories $2,434 25 payments
  4. Edwards Lifesciences Corporation $412 7 payments
  5. Medtronic, Inc. $296 4 payments
  6. Impulse Dynamics (USA) Inc. $162 1 payment
  7. HeartFlow, Inc. $109 4 payments
  8. Atricure, Inc. $92 3 payments
  9. Kestra Medical Technology Services, Inc. $84 1 payment
  10. Novartis Pharmaceuticals Corporation $32 2 payments
  11. Other $144 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,300 4 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,726 1 payment
  3. Food and Beverage $4,471 62 payments
  4. Travel and Lodging $3,488 13 payments
Products named General payments · program years 2019–2025
  1. General - Therapies General - Therapies_IC $6,884 7 payments
  2. GENERAL VASCULAR ACCESS $4,857 3 payments
  3. JARDIANCE $4,726 1 payment
  4. GENERAL - STRUCTURAL HEART $4,000 1 payment
  5. General - Therapies Therapies $1,396 5 payments
  6. GENERAL THERAPIES $1,071 5 payments
  7. MITRACLIP $196 3 payments
  8. AMPLATZER Occluders $187 1 payment
  9. NAVITOR $186 3 payments
  10. OPTIMIZER $162 1 payment
  11. Other $2,037 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

743

Median for Cardiology: 2,533

Drug cost

$130,353

Median for Cardiology: $485,213

Branded share of claims

28.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 61 $60,574
Entresto Sacubitril/Valsartan Brand 18 $23,186
Xarelto Rivaroxaban Brand 12 $16,449
Jardiance Empagliflozin Brand 11 $14,795
Brilinta Ticagrelor Brand 19 $8,691
Valsartan Generic 16 $854
Rosuvastatin Calcium Generic 72 $852
Carvedilol Generic 73 $668
Losartan Potassium Generic 52 $593
Ezetimibe Generic 56 $581

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$119,644

Medicare's payments for the services billed

Medicare patients

463

Average age 75

Services billed

1,099

215 women, 248 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 67%
Atrial fibrillation 56%
Chronic kidney disease 56%
Diabetes 54%
Arthritis 50%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $31
$31 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record